We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE) (RESOLVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01354405
Recruitment Status : Completed
First Posted : May 16, 2011
Last Update Posted : July 9, 2014
Information provided by (Responsible Party):
Radboud University

May 13, 2011
May 16, 2011
July 9, 2014
May 2011
June 2014   (Final data collection date for primary outcome measure)
Liver volume [ Time Frame: 24 weeks ]
Change in total liver volume between baseline and 24 weeks, as determined by CT volumetry
Same as current
Complete list of historical versions of study NCT01354405 on ClinicalTrials.gov Archive Site
  • Kidney volume [ Time Frame: 24 weeks ]
    Change in kidney volume between baseline and 24 weeks, as determined by CT volumetry
  • Glomerular filtration rate [ Time Frame: 24 weeks ]
    Change in GFR between baseline and 24 weeks, as determined by serum and 24 hrs urinary creatinine measurement
  • Urinary tubular damage markers [ Time Frame: 24 weeks ]
    Change in urinary tubular damage markers between baseline and 24 weeks
  • Symptoms [ Time Frame: 24 weeks ]
    Change in symptoms between baseline and 24 weeks, assessed by GI-questionnaire
  • Blood pressure [ Time Frame: 24 weeks ]
    Change in blood pressure between baseline and 24 weeks
  • quality of life [ Time Frame: 24 weeks ]
    Change in quality of life between baseline and 24 weeks, measured by EuroQoL-questionnaire
  • Adverse events [ Time Frame: 24 weeks ]
    All adverse events that occur during 24 weeks of treatment
Same as current
Not Provided
Not Provided
Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
The Effect of Lanreotide on Volume of Polycystic Liver and Kidney in Autosomal Dominant Polycystic Kidney Disease
The aim of this study is to determine the effect of Lanreotide on polycystic liver and kidneys in patients with autosomal dominant polycystic kidney disease.

The aim of this single center observational study is to assess the effect of lanreotide on polycystic liver and kidney. This is achieved by assessing total liver and kidney volume, and several urinary markers that could predict kidney damage or kidney dysfunction, such as GFR, blood pressure, and urinary tubular damage markers and serum biomarker FGF23.

The investigators aim to include 43 patients affected by a polycystic liver due to ADPKD. The duration of the trial will be 28 weeks. The treatment will be 24 weeks and the first screening visit will take place four weeks before start of treatment. Eligible patients will be invited to participate.

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Blood samples
Non-Probability Sample
ADPKD patients in Radboud University Hospital
Polycystic Liver Disease
Drug: Lanreotide
120 mg every 28 days intramuscular
Other Name: Somatuline
Intervention: Drug: Lanreotide

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
June 2014
June 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with ADPKD with polycystic liver (> 20 liver cysts)
  • Renal function MDRD >40 ml/hr
  • Informed consent, patients are willing and able to comply with the study drug regimen and all other study requirements

Exclusion Criteria:

  • Kidney transplantation
  • Renal failure requiring hemodialysis
  • Use of oral contraceptives or estrogen suppletion
  • Women who are pregnant or breastfeeding
  • History of cardiac/pulmonary disease; symptomatic gallstones, pancreatitis, etc
  • Intervention (aspiration or surgical intervention) within three months from baseline
  • Treatment with somatostatin analogues within three months from baseline
  • Mental illness that interferes with the patient ability to comply with the protocol
  • Drug or alcohol abuse within one year from baseline
  • Abnormal liver function tests, as determined by blood test (except isolated elevated GGT and AP, which occurs frequently in PLD)
  • Clinical diagnosis of pancreatitis
  • Diagnosis of diabetes mellitus, as determined by blood test and medical history
  • Use of drugs that can interact with lanreotide, such as cyclosporin
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
PCLD 10-03
Not Provided
Not Provided
Radboud University
Radboud University
Principal Investigator: Joost PH Drenth, MD, PhD Radboud University Hospital
Radboud University
July 2014